Phaseline

Targets › RBP4

RBP4 (Retinol-binding protein 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Feb 2028.

Retinol-binding protein that mediates retinol transport in blood plasma. Delivers retinol from the liver stores to the peripheral tissues (Probable). (UniProt, P02753)

Open in Phaseline: the race on RBP4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City TherapeuticsCITY-RBP4
siRNA targeting RBP4
RBP4Phase 1Stargardt Disease 1Feb 2028

Conditions

Stargardt Disease 1 (1)

Modalities

small molecule (1)

Companies

City Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.